Ad hoc announcement pursuant to Art. 53 LR

 

Straumann’s Bone Level Implant gains regulatory approval in Japan

  


 

 

  • Straumann now able to offer a comprehensive portfolio of soft tissue and bone level implant options to customers in Japan
  • Straumann Bone Level range now available in all key implant markets

 

 

 

Basel, 7 March 2011: Straumann today announced that its Bone Level dental implant has received approval from the Ministry of Health, Labor and Welfare in Japan and will become available there on 22 March 2011.

 

Introduced in initial markets at the end of 2007, the Straumann Bone Level implant complements the company’s range of highly successful Soft Tissue Level Implants. The Bone Level range is now available in all key implant markets and has become an important contributor to the Group’s growth. It has enabled Straumann to win new customers in addition to providing a complete range to existing clients.

 

The Straumann Bone Level Implant comes in three diameters and four lengths and addresses a broad range of tooth replacement indications. There is a full matching prosthetic portfolio comprising more than 120 components, each carefully designed for simplicity, reliability and esthetic performance. The new implant is available in Japan with Straumann’s renowned SLA surface technology, which is supported by 10-year clinical data. Approvals for the SLActive and Roxolid versions are pending.

 

Bone or Soft Tissue Level?

Dental implants broadly fall into two categories, depending on the level at which they connect to the prosthetic components that carry the tooth crown. In the case of tissue level implants, which were pioneered by Straumann, the connection is at the level of the gum. With bone level designs, the prosthetic connection is underneath the gum at, or close to, the crest of the jaw bone. While advantages are claimed for each design, market research shows that the choice of implant type is driven mainly by user preference1. In Japan, which is one of the world’s largest dental implant markets, Straumann estimates that possibly as many as 80%2 of implants placed are bone level.

 

 

About Straumann

Headquartered in Basel, Switzerland, the Straumann Group (SIX: STMN) is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 2360 people worldwide and its products and services are available in more than 70 countries through its broad network of distribution subsidiaries and partners.

  

References

1 Straumann estimates based on available market data and independent reports

2 Japanese Committee of Dental Implant Suppliers, Millennium Research Group 2009, Straumann estimates

 

 
  

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: corporate.communication@straumann.com or investor.relations@straumann.com

Homepage: www.straumann.com

 

 

Contacts:

 

Corporate Communication:

Mark Hill               

+41 (0)61 965 13 21

 

Thomas Konrad

+41 (0)61 965 15 46

 

 

Investor Relations:

Fabian Hildbrand

+41 (0)61 965 13 27

 

 

Disclaimer

This release contains certain “forward-looking statements”, which can be identified by the use of terminology such as ‘will’, ‘become’, ‘able to offer’, or similar wording. Such forward-looking statements reflect the current views of management and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Group to differ materially from those expressed or implied. These include risks related to the success of and demand for the Group’s products, the potential for the Group’s products to become obsolete, the Group’s ability to defend its intellectual property, the Group’s ability to develop and commercialize new products in a timely manner, the dynamic and competitive environment in which the Group operates, the regulatory environment, changes in currency exchange rates, the Group’s ability to generate revenues and profitability, and the Group’s ability to realize its expansion projects in a timely manner. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in it as a result of new information, future events or otherwise.

 

 

Downloads